in Ontario, Canada, yielded the first self-assembling TMV-based polio vaccine from an E. coli-expressed CP fusion protein, inducing neutralizing antibodies in rats [112]. Since then, tobamovirus-derived particles have increasingly been recognized as robust but tailorable, sustainably produced, and ...